Xention raises £8M; Maxygen distributes Codexis shares; Insurer counts costs of diabetes;

 @FierceBiotech: Biotech's Biggest Spenders 2010. Report | Follow @FierceBiotech

 @JohnCFierce: Proving yet again how hot antibody tech is, Boehringer agrees to $1.7B (provided all the stars align) pact with f-star. Article | Follow @JohnCFierce

> The UK's Xention closed an £8 million series D financing to fund the clinical development of its experimental therapies for atrial fibrillation. The financing was led by new investor Seroba-Kernel Life Sciences Ltd and included existing investors Forbion Capital Partners, Crédit Agricole Private Equity, MVM and BTG International. Xention secializes in the discovery and development of ion channel-modulating drugs. Xention release

Special Report: Big Pharma's Top 5 Emerging Market Deals. Report

> Maxygen announced plans to distribute all the shares it owns of Codexis along with $30 million in cash. Maxygen formed Codexis in January 2002 as a wholly owned subsidiary to operate its former chemicals business, and on April 27, 2010, Codexis completed an initial public offering of its common stock. Maxygen release

> BioCancell Therapeutics says it raised $5.1 million from a public offering. BioCancell release

Special Report: Pharma's Top 10 Blockbuster Drugs. Article

> India's Claris Lifesciences has received regulatory approval for an IPO. The Carlyle Group holds a 13.89% stake in Claris. Story

Special Report: Top 10 Generic Drug Companies 2010. Report

And Finally... The big insurer UnitedHealth says that an epidemic of diabetes could cost the U.S. $3.4 trillion over the next 10 years, unless we start to bend the growth rate. Report

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.